San Antonio Breast Cancer Symposium 2025

San Antonio Breast Cancer Symposium 2025
December 09-12, 2025
US - San Antonio, TX

San Antonio Breast Cancer Symposium 2025 .

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (5)

    Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study

    • Author(s): Punie, K
    • trodelvy
    • Oncology
    • Oral

    A retrospective observational multi-center study of Sacituzumab Govitecan in mTNBC post NHIA reimbursement in Taiwan (inSiGht)- an interim analysis

    • Author(s): Chou, H
    • trodelvy
    • Oncology
    • Poster

    Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07

    • Author(s): Jhaveri, K
    • trodelvy
    • Oncology
    • Oral

    Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)

    • Author(s): Kalinsky, K
    • trodelvy
    • Oncology
    • Poster

    Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan (SG) vs chemotherapy (chemo) for previously untreated advanced triple-negative breast cancer (TNBC) in patients (pts) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i)

    • Author(s): Hurvitz, S
    • trodelvy
    • Oncology
    • Poster